Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 540 of 5804
-
Can weight loss drugs boost heart function in obese heart failure patients?
Disease control Recruiting nowThe benefit of weight loss in patients with obesity and heart failure with reduced ejection fraction (HFrEF) is controversial. Semaglutide has shown cardiovascular (CV) risk-reduction and impact on CV risk factors including overweight, dysglycaemia and hypertension in subjects wi…
Phase: PHASE2, PHASE3 • Sponsor: Jens D Hove, MD,PHD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowProspective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pr…
Phase: PHASE3 • Sponsor: Octapharma • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Spinal stimulator aims to restore movement in paralyzed patients
Disease control Recruiting nowThe study aims to examine the plausible interventional mechanisms underlying the effects of epidural spinal cord stimulation.
Phase: NA • Sponsor: Buddhist Tzu Chi General Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered immune cells take on deadly brain tumors in first human trial
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatmen…
Phase: PHASE1 • Sponsor: Hideho Okada, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug pegtibatinase tested for rare metabolic disorder over two years
Disease control ENROLLING_BY_INVITATIONThe goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 …
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Head-to-Head chemo battle: which regimen works better for hodgkin lymphoma?
Disease control CompletedThe goal of this phase III clinical trial was to make a direct head to head comparison between the chemotherapeutics; Bendamustine, Gemcitabine and Vinorelbine (BEGEV) and the the Gemcitabine, Dexamethasone and Cisplatin (GDP) regimens in the settings of relapsed and refractory c…
Phase: PHASE3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One visit, two shots: study tests combining RSV and COVID vaccines for seniors
⭐️ VACCINE ⭐️ CompletedThis study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThe researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo shows promise for Tough-to-Treat skin cancer
Disease control OngoingStage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + t…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Goji berry trial hopes to shield aging eyes from vision loss
Prevention Recruiting nowThe goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a wee…
Phase: NA • Sponsor: University of California, Davis • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
RSV vaccine shows promise for High-Risk younger adults
⭐️ VACCINE ⭐️ CompletedThe aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and ab…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:51 UTC
-
Intensive weight loss program aims to transform care for severe obesity
Disease control Recruiting nowIn this trial, the aim is to assess the clinical benefits and harms, as well as cost-effectiveness of an intensive weight loss (IWL) intervention that includes total dietary replacements, behavioural support and weight-loss medication compared with existing weight management prog…
Phase: NA • Sponsor: Carsten Dirksen • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for blood cancer patients: experimental drug DZD8586 enters phase 2 trial
Disease control Recruiting nowThis study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type …
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThe study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TS…
Phase: PHASE1, PHASE2 • Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a quick second drug boost stroke recovery?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New gene therapy trial hopes to tame rare metabolic disease in kids
Disease control Recruiting nowPhase I, open-label, single-arm, single-dose, trial of VGM-R02b (gene replacement therapy) in patients with Glutaric Acidemia Type I (GA-I) who meet enrollment criteria and are genetically confirmed by GCDH gene mutation. 1 to 3 patients aged≤ 6 years at the time of screening wil…
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Fresh donor cells take on childhood leukemia in early trial
Disease control Recruiting nowThis is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory…
Phase: PHASE1 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New eczema cream shows promise in large trial
Symptom relief CompletedThis study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New hope for SMA babies: risdiplam trial launches in newborns
Disease control CompletedThis study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a simple chest strap replace invasive heart tests?
Diagnosis Recruiting nowPulmonary hypertension is a serious and progressive disease that is difficult to treat and diagnose, mainly because its symptoms are nonspecific and often delay recognition. Early diagnosis is a major challenge. Although several tests may suggest the disease, the definitive diagn…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:11 UTC